Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity (DUAL-HFrEF)
2026年7月30日 更新者：Shadi Shafaghi、Shahid Beheshti University of Medical Sciences
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial
The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide. The main questions it aims to answer are:
Does tirzepatide improve how far participants can walk in 6 minutes? Does tirzepatide improve heart failure symptoms and quality of life? What side effects do participants have when taking tirzepatide?
Researchers will compare tirzepatide to a placebo (a look-alike substance that contains no drug) to see if tirzepatide improves physical function in people with heart failure and obesity.
Participants will:
Get a weekly injection of tirzepatide or a placebo under the skin for 6 months Start at a low dose, which may be raised slowly based on how well they tolerate it Keep taking their usual heart failure medicines Visit the clinic for checkups, blood tests, heart ultrasounds, and a 6-minute walk test Answer questions about their quality of life and heart failure symptoms
研究概览
详细说明
This is a phase 3, randomized, double-blind (participant, care provider, investigator, and outcomes assessor blinded), placebo-controlled, parallel- group clinical trial evaluating the efficacy and safety of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, in participants with heart failure with reduced ejection fraction (HFrEF) and obesity.
Eligible participants are adults aged 18 years or older with HFrEF (left ventricular ejection fraction ≤40% on echocardiography within the prior 3 months), a body mass index ≥27 kg/m² with at least one obesity-related comorbidity (hypertension, diabetes, or dyslipidemia), and stable guideline-directed heart failure therapy for at least 4 weeks prior to enrollment. Key exclusion criteria include recent acute heart failure decompensation or hospitalization, uncontrolled blood pressure, advanced kidney disease (eGFR <30 mL/min/1.73m²), significant hepatic impairment, active pancreatitis, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and pregnancy or breastfeeding.
A total of 60 participants will be randomized 1:1 using a computer-generated block randomization schedule (block size of 4) to receive either tirzepatide or matching placebo, both administered as weekly subcutaneous injections. Study drug is initiated at 2.5 mg once weekly and titrated every 4 weeks, as tolerated, up to a maximum of 10 mg once weekly, continuing through month 6. The placebo pen is identical in appearance, packaging, and dosing schedule to maintain blinding.
The primary outcome is change in 6-minute walk distance from baseline to 6 months. Secondary outcomes include change in New York Heart Association functional class, Kansas City Cardiomyopathy Questionnaire quality-of-life score, body mass index, ejection fraction, pulmonary artery pressure, and metabolic parameters (fasting glucose, glycated hemoglobin, lipid panel), measured at baseline and at months 2, 4, and 6. Safety outcomes include gastrointestinal adverse events, injection-site reactions, hypoglycemia, pancreatitis, gallbladder events, and changes in liver enzymes, amylase, and lipase. An exploratory outcome evaluates shared molecular and genetic pathways linking obesity and HFrEF using peripheral blood RNA analysis via quantitative PCR or next-generation sequencing.
The study is being conducted at seven sites in Tehran, Iran, including Masih Daneshvari Hospital, Shahid Rajaei Cardiovascular Medical and Research Center, Rasoul Akram Hospital, Tehran Heart Center, Firoozgar Hospital, Ayatollah Taleghani Hospital, and Imam Khomeini Hospital Complex.
研究类型
介入性
注册 (估计的)
60
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Shadi Shafaghi, MD-MPH-PhD
- 电话号码：989125901135
- 邮箱：shafaghishadi@yahoo.com
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age 18 years or older
- Heart failure with reduced ejection fraction, defined as left ventricular ejection fraction ≤40% on echocardiography performed within the prior 3 months
- Body mass index ≥27 kg/m², with at least one obesity-related comorbidity (hypertension, diabetes, or dyslipidemia)
- Stable heart failure therapy for at least 4 weeks prior to enrollment, including beta-blockers, renin-angiotensin system inhibitors/angiotensin receptor-neprilysin inhibitors, and sodium-glucose cotransporter-2 inhibitors, if prescribed
- Written informed consent
Exclusion Criteria:
- Acute heart failure decompensation or cardiac hospitalization within the prior 4 weeks
- Uncontrolled blood pressure (systolic blood pressure <90 mmHg or ≥180 mmHg)
- Advanced renal impairment (estimated glomerular filtration rate <30 mL/min/1.73m²)
- Severe hepatic impairment (liver enzymes elevated to 3 times the upper limit of normal)
- Active pancreatitis
- Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Pregnancy or breastfeeding
- Known hypersensitivity to glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonist drugs
- Concurrent use of other weight-loss medications
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Tirzepatide
Participants receive tirzepatide via prefilled subcutaneous injection pen once weekly, in addition to standard heart failure therapy.
Starting dose is 2.5 mg once weekly for 4 weeks, titrated based on tolerability every 4 weeks up to a maximum of 10 mg once weekly, continued through month 6.
|
dual GLP-1/GIP receptor agonist administered subcutaneously; brief dosing summary
其他名称：
|
|
安慰剂比较：Placebo
Participants receive matching placebo via identical prefilled subcutaneous injection pen once weekly, in addition to standard heart failure therapy, with the same dosing schedule and titration pattern as the tirzepatide group, continued through month 6.
|
Matching placebo pen containing all inactive ingredients except tirzepatide
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in 6-Minute Walk Distance
大体时间：Baseline and 6 months after intervention start
|
The 6-minute walk test will be performed according to the American Thoracic Society standard guidelines in a straight 30-meter corridor.
Participants will be asked to walk as far as possible in 6 minutes at their own pace, with rest breaks permitted if needed.
Total distance walked will be recorded in meters.
This is a standardized, validated, and reproducible tool for assessing functional capacity and exercise tolerance in patients with heart failure.
|
Baseline and 6 months after intervention start
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
NYHA Functional Class
大体时间：Baseline and 6 months after intervention start
|
Heart failure severity classified according to the New York Heart Association (NYHA) functional classification system.
|
Baseline and 6 months after intervention start
|
|
Glycated Hemoglobin (HbA1c)
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Measured using standard biochemical assay kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Fasting Blood Glucose
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample collected after at least 8 hours of fasting; fasting glucose measured using standard enzymatic glucose oxidase laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Body Mass Index (BMI)
大体时间：Baseline and 6 months after intervention start
|
Calculated as weight in kilograms divided by height in meters squared, using standardized stadiometer and scale.
|
Baseline and 6 months after intervention start
|
|
Quality of Life (QoL)
大体时间：Baseline and 6 months after intervention start
|
Assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.
|
Baseline and 6 months after intervention start
|
|
Systolic Blood Pressure
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Measured using a calibrated automatic blood pressure device after at least 5 minutes of rest in a seated position.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Serum Amylase
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample; serum amylase measured using standard colorimetric enzymatic laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Alanine Aminotransferase (ALT)
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample; serum ALT measured using standard enzymatic spectrophotometric laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Measured using human NT-proBNP ELISA kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Total Cholesterol
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample collected after at least 8 hours of fasting; total cholesterol measured using standard colorimetric enzymatic laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Ejection Fraction
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Assessed by echocardiography.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Number of Participants With Gallbladder Problems
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Gallbladder problems (gallstones or cholecystitis) confirmed by abdominal ultrasound.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Number of Participants With Hypoglycemia
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Hypoglycemia, defined as blood glucose below 70 mg/dL, measured using standard enzymatic glucose oxidase laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Number of Participants With Injection Site Reactions
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Injection site reactions (including redness, swelling, itching, or pain at the injection site) assessed by physical examination.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Number of Participants With Gastrointestinal Adverse Events
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Gastrointestinal adverse events (including nausea, vomiting, diarrhea, constipation, or abdominal pain) graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and assessed through participant interview and monitoring form.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Number of Participants With Pancreatitis
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Pancreatitis diagnosed according to the revised Atlanta classification criteria, requiring at least two of the following: characteristic abdominal pain, serum amylase or lipase greater than three times the upper limit of normal, or characteristic findings on abdominal imaging.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Number of Participants With Tachycardia
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Tachycardia, defined as a resting heart rate greater than 100 beats per minute measured by pulse oximetry or ECG monitoring at scheduled study visits.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Diastolic Blood Pressure
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Measured using a calibrated automatic blood pressure device after at least 5 minutes of rest in a seated position.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Serum Lipase
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample; serum lipase measured using standard colorimetric enzymatic laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Aspartate Aminotransferase (AST)
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample; serum AST measured using standard enzymatic spectrophotometric laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Alkaline Phosphatase
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample; serum alkaline phosphatase measured using standard enzymatic spectrophotometric laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Low-Density Lipoprotein (LDL)
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample collected after at least 8 hours of fasting; serum LDL measured using standard colorimetric enzymatic laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
High-Density Lipoprotein (HDL)
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample collected after at least 8 hours of fasting; serum HDL measured using standard colorimetric enzymatic laboratory kit.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Triglycerides
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Venous blood sample collected after at least 8 hours of fasting; serum triglycerides measured using standard colorimetric enzymatic laboratory kit at the central laboratory.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
|
Pulmonary Artery Pressure
大体时间：Baseline, end of month 2, end of month 4, and end of month 6
|
Assessed by echocardiography.
|
Baseline, end of month 2, end of month 4, and end of month 6
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Gene Expression of Obesity- and Heart Failure-Related Pathways
大体时间：Baseline and 6 months after intervention start
|
Venous blood sampling before the intervention and at the end of the study, extraction of ribonucleic acid from peripheral blood samples, and assessment of changes in the expression of genes involved in the shared molecular pathways of obesity and Heart Failure with Reduced Ejection Fraction using quantitative real-time polymerase chain reaction (PCR).
|
Baseline and 6 months after intervention start
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Hinney A, Nguyen TT, Scherag A, Friedel S, Bronner G, Muller TD, Grallert H, Illig T, Wichmann HE, Rief W, Schafer H, Hebebrand J. Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants. PLoS One. 2007 Dec 26;2(12):e1361. doi: 10.1371/journal.pone.0001361.
- Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, Moller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, Nunez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC; STEP-HFpEF Trial Committees and Investigators. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
- Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol. 2022 May;19(5):291-301. doi: 10.1038/s41569-021-00638-w. Epub 2021 Nov 22.
- Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622-30. doi: 10.1126/science.3283935.
- Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-Melander M. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008 Feb;40(2):189-97. doi: 10.1038/ng.75. Epub 2008 Jan 13.
- Wallner M, Biber ME, Stolfo D, Sinagra G, Benson L, Dahlstrom U, Gudbjornsdottir S, Cosentino F, Mol PGM, Rosano GMC, Butler J, Metra M, Lund LH, Ferrannini G, Savarese G. Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):296-306. doi: 10.1093/ehjcvp/pvae026.
- Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Griffin R, Stefanski A, Garvey WT. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024 Jan;26(1):319-328. doi: 10.1111/dom.15318. Epub 2023 Nov 6.
- Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, Murakami M, Ou Y, Upadhyay N, Packer M. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025 Feb;31(2):544-551. doi: 10.1038/s41591-024-03374-z. Epub 2024 Nov 17.
- Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M, Packer M; SUMMIT Trial Study Group. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 2025 Mar 11;151(10):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. Epub 2024 Nov 18.
- Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16.
- Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H, Schou M, Melenovsky V, Abhayaratna W, Kitzman DW; STEP-HFpEF Trial Committees and Investigators. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2024 Jan 16;149(3):204-216. doi: 10.1161/CIRCULATIONAHA.123.067505. Epub 2023 Nov 12.
- Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K, Ezekowitz JA, Fu M, Melenovsky V, Ito H, Lelonek M, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. J Am Coll Cardiol. 2024 Jul 2;84(1):27-40. doi: 10.1016/j.jacc.2024.04.022. Epub 2024 May 13.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年7月18日
初级完成 (估计的)
2027年6月11日
研究完成 (估计的)
2027年12月22日
研究注册日期
首次提交
2026年7月27日
首先提交符合 QC 标准的
2026年7月30日
首次发布 (实际的)
2026年7月31日
研究记录更新
最后更新发布 (实际的)
2026年8月3日
上次提交的符合 QC 标准的更新
2026年7月30日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRCT20200209046427N3
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
是的
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.